

**12<sup>th</sup> International Workshop on Scleroderma Research - Cambridge, UK**  
**23<sup>rd</sup> – 27<sup>th</sup> July 2011**



Advancing Scleroderma  
 Research and  
 Translational Medicine

Scientific Steering Committee: David Abraham, Carol M Black, Christopher Denton, Carol Feghali-Bostwick, Armando Gabrielli, Thomas Krieg, Robert Lafyatis, Luc Mouthon, Marlene Rabinovitch, Kristopher Rubin, Maria Trojanowska, John Varga, Michael Whitfield

**PROGRAMME**

**SATURDAY 23<sup>rd</sup> JULY**

1-6 pm	REGISTRATION	
<b>OPENING LECTURE</b>		
<i>Chairs - Thomas Krieg and John Varga</i>		
6:30-7:30	Integrin-mediated adhesion and signalling in health and disease	REINHARD FASSLER
7:30	Drinks Reception	

**SUNDAY 24<sup>th</sup> JULY**

8am-6pm	REGISTRATION / POSTER SET UP (Frazer Room)	
8:45 am	WELCOME AND INTRODUCTION	CAROL BLACK & ROBERT LAFYATIS

<b>Session 1</b>		
<b>The Clinical and Research Challenges of Scleroderma</b>		
<i>Chairs - Daniel Furst and Jaap van Laar</i>		
09:00	Translational biology and new therapies	JOHN VARGA
09:35	Epigenetic modifications in SSc	BASHAR KHALEH
10:10	<i>Discussion</i>	
10:30	COFFEE BREAK	
<b>Session 2</b>		
<b>Immunology: Innate Immunity</b>		
<i>Chairs - Robert Lafyatis and Hans Stauss</i>		
11:00	Immune aspects of dendritic cells	TIMOTHY RADSTAKE
11:25	Apoptosis and the immune response	KEITH ELKON
11:50	Molecular diversity of the IFN pathway	PEGGY CROW
12:15	<i>Discussion</i>	
12:30	LUNCH	
<b>Session 3</b>		
<b>Infection and Environmental Triggers</b>		
<i>Chairs - Armando Gabrielli and Arnold Postlethwaite</i>		
1:30	Infections and autoimmunity	IRUN COHEN
1:55	Infectious diseases, innate immunity and fibrosis	CORY HOGABOAM
2:20	Nephrogenic Systemic Fibrosis as a scleroderma model	SERGIO JIMENEZ
2:45	<i>Discussion</i>	
3:00	TEA BREAK	

**12<sup>th</sup> International Workshop on Scleroderma Research - Cambridge, UK**  
**23<sup>rd</sup> – 27<sup>th</sup> July 2011**



Advancing Scleroderma  
Research and  
Translational Medicine

Scientific Steering Committee: David Abraham, Carol M Black, Christopher Denton, Carol Feghali-Bostwick, Armando Gabrielli, Thomas Krieg, Robert Lafyatis, Luc Mouthon, Marlene Rabinovitch, Kristopher Rubin, Maria Trojanowska, John Varga, Michael Whitfield

**SUNDAY 24<sup>th</sup> JULY (continued)**

<b>Session 4</b>		
<b>Young Investigators</b>		
<i>Chairs - Carol Black and Robert Lafyatis</i>		
3:30	Introduction	
	Top Five Abstract Awards Winners (10 minute presentations)	
4:30	END OF SESSION	
5:30-7:00	<b>POSTER VIEWING</b>	

**12<sup>th</sup> International Workshop on Scleroderma Research - Cambridge, UK**  
**23<sup>rd</sup> – 27<sup>th</sup> July 2011**



Advancing Scleroderma  
 Research and  
 Translational Medicine

Scientific Steering Committee: David Abraham, Carol M Black, Christopher Denton, Carol Feghali-Bostwick, Armando Gabrielli, Thomas Krieg, Robert Lafyatis, Luc Mouthon, Marlene Rabinovitch, Kristopher Rubin, Maria Trojanowska, John Varga, Michael Whitfield

**MONDAY 25<sup>th</sup> JULY**

<b>Session 5</b>		
<b>Inflammation and Mesenchymal Stroma</b>		
<i>Chairs - Kristofer Rubin and Maria Trojanowska</i>		
09:00	Effects of matrix density on cellular phenotype (not only in carcinoma)	VALERIE WEAVER
09:25	Regulation of Extracellular Matrix Production by Hypoxia: Implications for Cancer and Fibrosis	AMATO GIACCIA
09:50	Stromal reactions in carcinoma and its similarity and differences to tissue fibrosis	MIKE OSTROWSKI
10:15	LOXL2 in pathologic fibrotic microenvironment	VICTORIA SMITH
10:40	<i>Discussion</i>	
10:50	COFFEE BREAK	
<b>Session 6</b>		
<b>What causes Scleroderma? General Round Table Discussion Session</b>		
<i>Chairs - Bashar Kahaleh, Maureen Mayes, Neil McHugh, Arnold Postlethwaite, Timothy Radstake, Douglas Veale, Ken Welsh</i>		
11:20	Introduction and Round Table Discussion	
12:45	LUNCH	
<b>Session 7</b>		
<b>Genomics and Post-Genomics</b>		
<i>Chairs - John Varga and Michael Whitfield</i>		
1:45	Methylation determines fibroblast activation and fibrogenesis in the kidney	MICHAEL ZEISBERG
2:10	Transcriptional analysis of models -- Comparative analysis	MICHAEL WHITFIELD
2:35	Genetic of complex autoimmune diseases	JAVIER MARTIN
3:00	<i>Discussion</i>	
3:15	TEA BREAK	
<b>Session 8</b>		
<b>Novel Regulatory Pathways in Fibrosis</b>		
<i>Chairs - Humphrey Gardner and Marco Matucci Cerinic</i>		
3:45	Sphingosine 1 phosphate in health and disease	NIGEL PYNE
4:10	Non canonical WNT signalling in fibrosis and angiogenesis	FRANCESCO DEL GALDO
4:35	Epithelial cells promote dermal fibroblast activation via IL-1 $\alpha$ in systemic sclerosis	RICHARD STRATTON
5:00	<i>Discussion</i>	
5:15	<i>END OF SESSION</i>	
7:30	<b>BANQUET</b> <i>SPEAKER: SIR GREGORY WINTER</i>	

**12<sup>th</sup> International Workshop on Scleroderma Research - Cambridge, UK**  
**23<sup>rd</sup> – 27<sup>th</sup> July 2011**



Advancing Scleroderma  
 Research and  
 Translational Medicine

Scientific Steering Committee: David Abraham, Carol M Black, Christopher Denton, Carol Feghali-Bostwick, Armando Gabrielli, Thomas Krieg, Robert Lafyatis, Luc Mouthon, Marlene Rabinovitch, Kristopher Rubin, Maria Trojanowska, John Varga, Michael Whitfield

**TUESDAY 26<sup>th</sup> JULY**

<b>Session 9</b>		
<b>The Fibrillin Area and Fibrosis</b>		
<i>Chairs - Thomas Krieg and Kristofer Rubin</i>		
09:00	Fibrillins: Key extracellular determinants of tissue formation and fibrosis	FRANCESCO RAMIREZ
09:25	Mechanisms of TGF- $\beta$ activation	DAN RIFKIN
09:50	Fibrillin related diseases	ELIZABETH GERBER
10:15	<i>Discussion</i>	
10:30	COFFEE BREAK	
<b>Session 10 – Models Systems (In vitro and in vivo approaches)</b>		
<i>Chairs - James Tomasek and Robert Lafyatis</i>		
11:00	Fibroblast biomechanical cues as key regulators of matrix remodelling	BORIS HINZ
11:25	Targeting fibroblasts in vivo	ANDREW LEASK
11:50	Chemical induced models – strengths and weaknesses	OLIVER DISTLER
12:15	<i>Discussion</i>	
12:30	LUNCH	
<b>Session 11 – Biomarkers and Disease Classification/New Technology Areas</b>		
<i>Chairs - Luc Mouthon and Philip Clements</i>		
1:30	The Resolution of Inflammation: Players and Targets	MAURO PERETTI
1:55	Contribution of proteomics to the identification of biomarkers in vascular diseases	LUC MOUTHON
2:20	Identification of biomarkers in systemic sclerosis	ROBERT LAFYATIS
2:45	Composite measures of disease outcome – lessons from PF-SSc	LESLEY ANN SAKETKOO
3:10	<i>Discussion</i>	
3:30	<i>END OF SESSION</i>	
	<i>AFTERNOON TEA</i>	

**12<sup>th</sup> International Workshop on Scleroderma Research - Cambridge, UK**  
**23<sup>rd</sup> – 27<sup>th</sup> July 2011**



Advancing Scleroderma  
 Research and  
 Translational Medicine

Scientific Steering Committee: David Abraham, Carol M Black, Christopher Denton, Carol Feghali-Bostwick, Armando Gabrielli, Thomas Krieg, Robert Lafyatis, Luc Mouthon, Marlene Rabinovitch, Kristopher Rubin, Maria Trojanowska, John Varga, Michael Whitfield

**WEDNESDAY 27<sup>th</sup> JULY**

<b>Session 12</b>		
<b>Vascular Pathology and Remodelling in PAH</b>		
<i>Chairs - Lucie Clapp and Clive Handler</i>		
09:00	Future therapy of pulmonary arterial hypertension: reversing advanced disease	RUBIN TUDER
09:25	Molecular mechanism of the TNF superfamily in PAH	ALLAN LAWRIE
09:50	The role of TGFbeta in heritable PAH	ALAN HOLMES
10:15	Oestrogen and the serotonin system in the development of PAH	MARGARET MACLEAN
10:40	<i>Discussion</i>	
11:00	COFFEE BREAK	
<b>Session 13</b>		
<b>Applying Cell Biology to Human Disease</b>		
<i>Chairs - Christopher Denton and Ariane Herrick</i>		
11:30	Biomarkers of cancer risk and molecular targets for early Intervention	JILL SIEGFRIED
11:55	Therapeutic opportunities offered by reversible ubiquitination	MICHAEL CLAGUE
12:20	<i>Discussion</i>	
12:30-12:40	Future perspectives for the 2013 Workshop	CAROL BLACK & ROBERT LAFYATIS
12:40	LUNCH	
<b>Session 14</b>		
<b>Scleroderma Clinical Trials Consortium</b>		
<i>Chair - Peter Merkel</i>		
1:00	Update on the EULAR Points to Consider Project	DINESH KHANNA
1:15	Update on the ACR-EULAR Scleroderma Classification Project	DINESH KHANNA
<b>Interactive Session – Clinical trial design in scleroderma: Where do we go next?</b>		
1:30	Introduction	PETER MERKEL
1:40	Discussion- Primary outcome for clinical trials: Skin vs. lung vs. composite	CHRIS DENTON, Leader
2:00	Discussion-Digital ulcers in scleroderma: Healing vs. repair vs. composite	LORI CHUNG, Leader
2:20	Discussion-Pulmonary arterial hypertension in scleroderma	OLIVER DISTLER, Leader
3:00	Discussion-Relatively unstudied aspects of scleroderma: Opportunities for study or of lower priority and feasibility?	DANIEL FURST, Leader
3:20	Discussion-Summary and wrap up: What are the priorities?	PETER MERKEL, Leader
<b>END OF WORKSHOP</b>		